Epilepsy Research Reveals Demographic and Comorbidity Barriers to Therapy Revision

Strategic Insights -

Recent studies from the Institute of Neuroscience and Physiology have shed light on the challenges facing individuals with epilepsy, particularly those with comorbidities such as dementia and cerebrovascular disease. According to a report published in Brain and Behavior, the likelihood of revising the first antiseizure medication (ASM) is influenced by a range of factors, including age, sex, and pre-existing medical conditions.

Key Takeaways:

  • The first ASM fails due to side effects or continued seizures in approximately 50% of cases.
  • Patient demographics, such as age and sex, and comorbidities, such as cerebrovascular disease and dementia, significantly impact the likelihood of therapy revision.
  • Older patients with epilepsy and those with cerebrovascular disease or dementia are less likely to change the first ASM, suggesting a disadvantage in current healthcare systems.
  • Women are more likely to revise their first treatment compared to men.
  • Patients with brain infections and brain tumors are more likely to revise their first treatment.

Statistics:

  • 44,185 individuals with incident epilepsy between 2007 and 2019 were included in the study.
  • 50% of patients experience treatment failure with the first ASM due to side effects or continued seizures.
  • The likelihood of revising the first ASM decreases by 0.993% for each year of age (HR = 0.993, 95% CI: 0.992-0.993).
  • Patients with cerebrovascular disease are 19% less likely to revise the first ASM (HR = 0.81, 95% CI: 0.78-0.85).
  • Patients with dementia are 37% less likely to revise the first ASM (HR = 0.63, 95% CI: 0.58-0.69).
  • Women have a 14% increased likelihood of revising their first treatment (HR = 1.14, 95% CI: 1.10-1.19).
  • Patients with brain infections have a 21% increased likelihood of revising their first treatment (HR = 1.21, 95% CI: 1.08-1.35).
  • Patients with brain tumors have a 31% increased likelihood of revising their first treatment (HR = 1.31, 95% CI: 1.23-1.39).

Sources:

  • Institute of Neuroscience and Physiology, Department of Clinical Neuroscience
  • Brain and Behavior, volume 15, issue 10, 2025 (https://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2157-9032)
  • Mental Health Weekly Digest, November 3, 2025, p 219.